Graftys entered into a distribution agreement whereby OrthoPediatrics will market Graftys® QuickSet bone cement in the U.S. under the tradename QuickPack™.
QuickSet is a new generation macroporous calcium phosphate cement designed with an optimal natural cellular resorption/substitution cycle with a calcium-deficient apatite matrix that is structurally and chemically similar to native bone crystals. QuickSet employs a full range of micro- and macropores and compressive strength in the range of cancellous bone.
Graftys QuickSet/QuickPack is delivered in a closed loop double-compartment syringe specifically designed for safety, reproducibility and ease-of-use, with no risk of preparation mistake and no product loss.
Enrico Bastianelli, Chief Executive Officer of Graftys, said, “By choosing us, OrthoPediatrics offers to our products a wider and focused access to the U.S. territory. This new partnership reinforces our desire to continue to respond to the clinical issues faced daily by orthopedic surgeons.”
Graftys entered into a distribution agreement whereby OrthoPediatrics will market Graftys® QuickSet bone cement in the U.S. under the tradename QuickPack™.
QuickSet is a new generation macroporous calcium phosphate cement designed with an optimal natural cellular resorption/substitution cycle with a calcium-deficient apatite matrix that is...
Graftys entered into a distribution agreement whereby OrthoPediatrics will market Graftys® QuickSet bone cement in the U.S. under the tradename QuickPack™.
QuickSet is a new generation macroporous calcium phosphate cement designed with an optimal natural cellular resorption/substitution cycle with a calcium-deficient apatite matrix that is structurally and chemically similar to native bone crystals. QuickSet employs a full range of micro- and macropores and compressive strength in the range of cancellous bone.
Graftys QuickSet/QuickPack is delivered in a closed loop double-compartment syringe specifically designed for safety, reproducibility and ease-of-use, with no risk of preparation mistake and no product loss.
Enrico Bastianelli, Chief Executive Officer of Graftys, said, “By choosing us, OrthoPediatrics offers to our products a wider and focused access to the U.S. territory. This new partnership reinforces our desire to continue to respond to the clinical issues faced daily by orthopedic surgeons.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.